Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
5 Results Found
To Measure or Not to Measure: Overcoming Benchmarking Anxiety
With the biennial DEI benchmark survey now available through March 15, read AHA’s Leon Caldwell’s blog addressing the hesitancy related to taking the survey, as well as strategies to manage said anxieties. For questions related to your participation in the survey, please contact AHA’s survey support team at surveysupport@aha.org.
CMS announces two drug manufacturers to participate in CGT Access Model
The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of Lyfgenia) and Vertex Pharmaceuticals (manufacturer of Casgevy) will participate in its Cell and Gene Therapy Access Model.
CMS releases request for state applications for Cell and Gene Therapy Access Model targeting sickle cell disease
The Centers for Medicare & Medicaid Services June 28 announced the request for state applications for the Cell and Gene Therapy Access Model.
Agencies seek to address syphilis epidemic
U.S. syphilis cases surged 80% between 2018 and 2022, with congenital syphilis cases nearly tripling to 3,755, over 10 times the number in 2012, the Centers for Disease Control and Prevention reported Jan 30.
Chair File: How COVID-19 Will Reshape Health Care: 10 Predictions
As we forge ahead in 2021 facing a lot of uncertainty, there’s one thing we recognize: The COVID-19 pandemic will have a lasting effect on the health and well-being of our nation.